Annovis Bio Inc.
ANVS | NYSE
$1.26
+$0.07 (+5.88%)
Sep 22, 2026, 12:23 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -29.7M | -26.69M | -45.04M | -25.51M | -14.54M | -6.64M |
Interest Income | 699.06K | 331.85K | 667.9K | 182.71K | 13.34K | 47.23K |
Pretax Income | -28.85M | -24.59M | -56.2M | -25.33M | -14.49M | -5.46M |
Net Income | -28.85M | -24.59M | -56.2M | -25.33M | -14.49M | -5.46M |
Selling & General & Admin | 4.48M | 6.7M | 6.24M | 9M | 6.06M | 3.59M |
Research & Development | 25.22M | 20M | 38.79M | 16.52M | 8.48M | 3.05M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 29.7M | 26.69M | 45.04M | 25.51M | 14.54M | 6.64M |
Interest Expense | n/a | 1.85M | n/a | n/a | n/a | 47.23M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 29.7M | 26.69M | 45.04M | 25.51M | 14.54M | 6.64M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 20.55M | 12.18M | 9.02M | 8.16M | 7.63M | 6.31M |
Shares Outstanding (Diluted) | 20.55M | 12.24M | 9.02M | 8.16M | 7.63M | 6.31M |
EPS (Basic) | -1.40 | -2.02K | -6.23 | -3.10 | -1.90 | -0.87 |
EPS (Diluted) | -1.40 | -2.01K | -6.23 | -3.10 | -1.90 | -0.87 |
EBITDA | -28.85M | -22.74M | -56.2M | -25.33M | -14.5M | n/a |
EBIT | -28.85M | -22.74M | -56.2M | -25.33M | -14.5M | -6.64M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | 6.64M |
Add to Watchlist
Select watchlists to add or remove ANVS